Source: http://www.google.com/patents/US6416777?dq=7,194,691
Timestamp: 2014-03-07 13:37:00
Document Index: 250132805

Matched Legal Cases: ['art 15', 'art 18', 'art 15', 'art 18', 'art 15', 'art 18', 'art 18', 'art 15', 'art 15', 'art 17', 'art 18', 'art 17', 'art 18', 'art 17', 'art 17', 'art 18', 'art 18', 'art 15', 'art 18', 'art 15', 'art 18', 'art 15', 'art 18', 'art 15', 'art 18']

Patent US6416777 - Ophthalmic drug delivery device - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsThe present invention is directed to a drug delivery device for a human eye. The human eye has a sclera, an inferior oblique muscle, and a macula. The device of the present invention includes a pharmaceutically active agent, and a geometry that facilitates the implantation of the device on an outer surface...http://www.google.com/patents/US6416777?utm_source=gb-gplus-sharePatent US6416777 - Ophthalmic drug delivery deviceAdvanced Patent SearchPublication numberUS6416777 B1Publication typeGrantApplication numberUS 09/664,790Publication dateJul 9, 2002Filing dateSep 19, 2000Priority dateOct 21, 1999Fee statusPaidAlso published asCA2384255A1, CA2384255C, CN1376042A, CN100341470C, DE60018298D1, DE60018298T2, EP1221919A1, EP1221919B1, US6669950, US20030003129, US20040131654, US20040131655, WO2001028474A1Publication number09664790, 664790, US 6416777 B1, US 6416777B1, US-B1-6416777, US6416777 B1, US6416777B1InventorsYoseph YaacobiOriginal AssigneeAlcon Universal Ltd.Export CitationBiBTeX, EndNote, RefManPatent Citations (56), Non-Patent Citations (11), Referenced by (31), Classifications (13), Legal Events (6) External Links: USPTO, USPTO Assignment, EspacenetOphthalmic drug delivery deviceUS 6416777 B1Abstract The present invention is directed to a drug delivery device for a human eye. The human eye has a sclera, an inferior oblique muscle, and a macula. The device of the present invention includes a pharmaceutically active agent, and a geometry that facilitates the implantation of the device on an outer surface of the sclera, beneath the inferior oblique muscle, and with the pharmaceutically active agent disposed above the macula. Methods of delivery a pharmaceutically active agent to the posterior segment of the human eye are also disclosed.
What is claimed is: 1. A drug delivery device for a human eye, said eye having a sclera, an inferior oblique muscle, and a macula, said device comprising:
a pharmaceutically active agent; a body having a scleral surface for placement proximate an outer surface of said sclera and a well having an opening to said scleral surface; an inner core disposed in said well comprising said pharmaceutically active agent; and a geometry that facilitates an implantation of said device on said outer surface of said sclera, beneath said inferior oblique muscle, and with said pharmaceutically active agent disposed above said macula. 2. The drug delivery device of claim 1 wherein said geometry is a generally F-shaped geometry.
3. The drug delivery device of claim 1 wherein said geometry is a generally C-shaped geometry.
4. The drug delivery device of claim 1 wherein said geometry is a generally L-shaped geometry.
5. The drug delivery device of claim 1 wherein said body comprises a biocompatible, non-bioerodable material.
6. The drug delivery device of claim 1 wherein said body comprises a polymeric composition.
7. The drug delivery device of claim 6 wherein said polymeric composition comprises one or more polymers selected from the group consisting of silicone, polyvinyl alcohol, ethylene vinyl acetate, polylactic acid, nylon, polypropylene, polycarbonate, cellulose, cellulose acetate, polyglycolic acid, polylactic glycolic acid, cellulose esters, polyethersulfone, and acrylics.
8. The drug delivery device of claim 7 therein said polymeric composition comprises silicone.
9. The drug delivery device of claim 1 wherein said body is impermeable to said pharmaceutically active agent.
10. The drug delivery device of claim 1 wherein said inner core is a tablet.
11. The drug delivery device of claim 1 wherein said inner core comprises a semi-solid form, and said pharmaceutically active agent is disposed within said semi-solid form.
12. The drug delivery device of claim 1 wherein said human eye comprises a Tenon's capsule, and said body comprises an orbital surface having a radius of curvature that facilitates said implantation of said device below said Tenon's capsule.
13. The drug delivery device of claim 1 wherein said scleral surface has a radius of curvature substantially equal to the radius of curvature of said human eye.
14. The drug delivery device of claim 1 wherein said pharmaceutically active agent is nepafenac.
15. The drug delivery device of claim 1 wherein said pharmaceutically active agent comprises a compound selected from the group consisting of 4,9(11)-Pregnadien-17α,21-diol-3,20-dione and 4,9(11)-Pregnadien-17α,21-diol-3,20-dione-21-acetate.
16. The drug delivery device of claim 1 wherein said pharmaceutically active agent comprises eliprodil.
17. The drug delivery device of claim 1 further comprising a retaining member extending from said body proximate said opening.
18. The drug delivery device of claim 1 wherein said body comprises a notch for facilitating an accommodation of said inferior oblique muscle during said implantation of said device.
19. The drug delivery device of claim 18 wherein said notch comprises a ramp.
20. A method of delivering a pharmaceutically active agent to a human eye, said human eye having a sclera, an inferior oblique muscle, and a macula, comprising the steps of:
providing a drug delivery device comprising: a pharmaceutically active agent; a body having a scleral surface for placement proximate an outer surface of said sclera and a well having an opening to said scleral surface; and an inner core disposed in said well comprising said pharmaceutically active agent; and disposing said device on said outer surface of said sclera, beneath said inferior oblique muscle, and with said pharmaceutically active agent disposed above said macula. 21. The method of claim 20 wherein said disposing step comprises disposing said device beneath a Tenon's capsule of said human eye.
22. The method of claim 20 wherein said body comprises a biocompatible, non-bioerodable material.
23. The method of claim 20 wherein said inner core is a tablet.
24. The method of claim 20 wherein said inner core comprises a semi-solid form, and said pharmaceutically active agent is disposed within said semi-solid form.
25. The method of claim 20 wherein said body is impermeable to said pharmaceutically active agent.
26. The method of claim 20 wherein said scleral surface has a radius of curvature substantially equal to the radius of curvature of said human eye.
27. The method of claim 20 wherein said pharmaceutically active agent comprises a compound selected from the group consisting of 4,9(11)-Pregnadien-17α,21-diol-3,20-dione and 4,9(11)-Pregnadien-17α,21-diol-3,20-dione-21-acetate.
28. The method of claim 20 wherein said pharmaceutically active agent comprises eliprodil.
29. The method of claim 20 wherein said body comprises a notch, and wherein said disposing step comprises disposing a scleral side of said inferior oblique muscle in said notch.
30. The method of claim 20 wherein said device has a generally F-shaped geometry.
31. The method of claim 20 wherein said device has a generally C-shaped geometry.
32. The method of claim 20 wherein said device has a generally L-shaped geometry.
33. The method of claim 20 wherein said pharmaceutically active agent is nepafenac.
This application claims the benefit of U.S. Provisional Application Serial No. 60/160,673, filed Oct. 21, 1999, entitled �Drug Delivery Device�, and incorporated herein by this reference.
FIELD OF THE INVENTION The present invention generally pertains to biocompatible implants for localized delivery of pharmaceutically active agents to body tissue. More particularly, but not by way of limitation, the present invention pertains to biocompatible implants for localized delivery of pharmaceutically active agents to the posterior segment of the eye.
DESCRIPTION OF THE RELATED ART Several diseases and conditions of the posterior segment of the eye threaten vision. Age related macular degeneration (ARMD), choroidal neovascularization (CNV), retinopathies (e.g., diabetic retinopathy, vitreoretinopathy), retinitis (e.g., cytomegalovirus (CMV) retinitis), uveitis, macular edema, glaucoma, and neuropathies are several examples.
In the particular case of CNV in ARMD, three main methods of treatment are currently being developed, (a) photocoagulation, (b) the use of angiogenesis inhibitors, and (c) photodynamic therapy. Photocoagulation is the most common treatment modality for CNV. However, photocoagulation can be harmful to the retina and is impractical when the CNV is near the fovea. Furthermore, over time, photocoagulation often results in recurrent CNV. Oral or parenteral (non-ocular) administration of anti-angiogenic compounds is also being tested as a systemic treatment for ARMD. However, due to drug-specific metabolic restrictions, systemic administration usually provides subtherapeutic drug levels to the eye. Therefore, to achieve effective intraocular drug concentrations, either an unacceptably high dose or repetitive conventional doses are required. Periocular injections of these compounds often result in the drug being quickly washed out and depleted from the eye, via periocular vasculature and soft tissue, into the general circulation. Repetitive intraocular injections may result in severe, often blinding, complications such as retinal detachment and endophthalmitis. Photodynamic therapy is a new technology for which the long-term efficacy is still largely unknown.
SUMMARY OF THE INVENTION The present invention is directed to a drug delivery device for a human eye. The human eye has a sclera, an inferior oblique muscle, and a macula. The device of the present invention includes a pharmaceutically active agent, and a geometry that facilitates the implantation of the device on an outer surface of the sclera, beneath the inferior oblique muscle, and with the pharmaceutically active agent disposed above the macula. Because of its unique geometry, the device is especially useful for localized delivery of pharmaceutically active agents to the posterior segment of the eye to combat ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, glaucoma, and neuropathies.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The preferred embodiments of the present invention and their advantages are best understood by referring to FIGS. 1 through 21 of the drawings, like numerals being used for like and corresponding parts of the various drawings.
Device 50 generally includes a body 21 having a convex, dome-shaped, orbital surface 12 and a concave, dome-shaped, scleral surface 14. Scleral surface 14 is designed with a radius of curvature that facilitates direct contact with sclera 100. Most preferably, scleral surface 14 is designed with a radius of curvature equal to the radius of curvature 91 of an average human eye 90. (See FIG. 1) Orbital surface 12 is preferably designed with a radius of curvature that facilitates implantation under Tenon's capsule 101. When viewed from the top, body 21 preferably has a generally �F-shaped� geometry with a longitudinal part 15, a transversal part 18, and a knee 32 therebetween. Longitudinal part 15 and transversal part 18 are preferably joined at knee 32 to form an angle of about ninety degrees. Longitudinal part 15 has a proximal end 25, a rounded edge 24, a stopper 36, and a notch 42. As is described in more detail hereinbelow, notch 42 is designed to accommodate the origin of inferior oblique muscle 107. Stopper 36 defines the lower portion of notch 42 and is preferably slightly elevated from the remainder of the generally convex orbital surface 12. As is described in greater detail hereinbelow, stopper 36 is designed to prevent excessive advancement of device 50 toward optic nerve 96 through contact on the anterior border of inferior oblique muscle 107. Transversal part 18 has a distal end 58, a rounded edge 28, and a well or cavity 20 having an opening 64 to scleral surface 14. Well 20 and opening 64 preferably have a generally oval shape. As is explained in more detail hereinbelow, transversal part 18 allows cavity 20 to be placed more directly over the area of sclera 100 overlying macula 98.
Body 21 preferably comprises a biocompatible, non-bioerodable material. Body 21 more preferably comprises a biocompatible, non-bioerodable polymeric composition. Said polymeric composition may be a homopolymer, a copolymer, straight, branched, cross-linked, or a blend. Examples of polymers suitable for use in said polymeric composition include silicone, polyvinyl alcohol, ethylene vinyl acetate, polylactic acid, nylon, polypropylene, polycarbonate, cellulose, cellulose acetate, polyglycolic acid, polylactic-glycolic acid, cellulose esters, polyethersulfone, acrylics, their derivatives, and combinations thereof. Examples of suitable soft acrylics are more fully disclosed in U.S. Pat. No. 5,403,901, which is incorporated herein in its entirety by reference. Said polymeric composition most preferably comprises silicone. Of course, said polymeric composition may also comprise other conventional materials that affect its physical properties, including, but not limited to, porosity, tortuosity, permeability, rigidity, hardness, and smoothness. Exemplary materials affecting certain ones of these physical properties include conventional plasticizers, fillers, and lubricants. Said polymeric composition may comprise other conventional materials that affect its chemical properties, including, but not limited to, toxicity, hydrophobicity, and body 21�inner core 81 interaction. Body 21 is preferably impermeable to the pharmaceutically active agent of inner core 81. When body 21 is made from a generally elastic polymeric composition, the shape of well 20 may be made slightly smaller than the shape of inner core 81. This frictional fit secures inner core 81 within well 20. In this embodiment, body 21 may be formed with or without retaining member 62, and inner core 81 may be formed with or without bevel 87, if desired.
Inner core 81 may comprise any ophthahnically acceptable pharmaceutically active agents suitable for localized delivery. Examples of pharmaceutically active agents suitable for inner core 81 are anti-infectives, including, without limitation, antibiotics, antivirals, and antifungals; antiallergenics and mast cell stabilizers; steroidal and non-steroidal anti-inflammatory agents; cyclooxygenase inhibitors, including, without limitation, Cox I and Cox II inhibitors; combinations of anti-infective and anti-inflammatory agents; anti-glaucoma agents, including, without limitation, adrenergics, βadrenergic blocking agents, α-adrenergic agonists, parasypathomimetic agents, cholinesterase inhibitors, carbonic anhydrase inhibitors, and prostaglandins; combinations of anti-glaucoma agents; antioxidants; nutritional supplements; drugs for the treatment of cystoid macular edema including, without limitation, non-steroidal anti-inflammatory agents; drugs for the treatment of ARMD, including, without limitation, angiogenesis inhibitors and nutritional supplements; drugs for the treatment of herpetic infections and CMV ocular infections; drugs for the treatment of proliferative vitreoretinopathy including, without limitation, antimetabolites and fibrinolytics; wound modulating agents, including, without limitation, growth factors; antimetabolites; neuroprotective drugs, including, without limitation, eliprodil; and angiostatic steroids for the treatment of diseases or conditions of the posterior segment of the eye, including, without limitation, ARMD, CNV, retinopathies, retinitis, uveitis, macular edema, and glaucoma. Such angiostatic steroids are more fully disclosed in U.S. Pat. Nos. 5,679,666 and 5,770,592, which are incorporated herein in their entirety by reference. Preferred ones of such angiostatic steroids include 4,9(11)-Pregnadien-17α,21-diol-3,20-dione and 4,9(11)-Pregnadien- 17α,21-diol-3,20-dione-21-acetate. A preferred non-steroidal anti-inflammatory for the treatment of cystoid macular edema is nepafenac. Inner core 81 may also comprise conventional non-active excipients to enhance the stability, solubility, penetrability, or other properties of the active agent or the drug core.
It is believed that device 50 can be used to deliver a pharmaceutically effective amount of a pharmaceutically active agent to retina 97 for many years, depending on the particular physicochemical properties of the pharmaceutically active agent employed. Important physicochemical properties include hydrophobicity, solubility, dissolution rate, diffusion coefficient, partitioning coefficient, and tissue affinity. After inner core 20 no longer contains active agent, the surgeon may easily remove device 50. In addition, the �preformed� tunnel facilitates the replacement of an old device 50 with a new device 50.
FIGS. 16 schematically illustrates an ophthalmic drug delivery device 40, a slight modification of ophthalmic drug delivery device 50 that is useful for certain implantations of the present invention. As shown in FIG. 16, device 40 has a geometry substantially similar to device 50 of FIGS. 7 and 9, with the exception that a length of longitudinal part 15 in device 40 has been shortened relative to device 50. Similar to device 30, this shortening of longitudinal part 15 may result in device 40 being more comfortable or cosmetically acceptable to the patient. The use of device 40 of FIG. 16 is substantially similar to the use of device 50, and device 40 may be made using techniques substantially similar to device 50.
Device 65 generally includes a body 29 having a convex, dome-shaped, orbital surface 12 and a concave, dome-shaped, scleral surface 14 (not shown). Scleral surface 14 is designed with a radius of curvature that facilitates direct contact with sclera 100. Most preferably, scleral surface 14 is designed with a radius of curvature equal to the radius of curvature 91 of an average human eye 90. Orbital surface 12 is preferably designed with a radius of curvature that facilitates implantation under Tenon's capsule 101. When viewed from the top, body 21 preferably has a generally �C-shaped� geometry with a longitudinal part 17, a transversal part 18, and a knee 32 therebetween. Longitudinal part 17 and transversal part 18 are preferably joined at knee 32 to form an angle of about ninety degrees. Longitudinal part 17 has a proximal end 25 and a rounded edge 24. A stopper 37 forms the �lower� part of the C-shaped geometry and is preferably slightly elevated from the remainder of the generally convex orbital surface 12. A notch 42 is located in longitudinal part 17 and is defined by transversal part 18 and stopper 37. Similar to notch 42 of device 50 of FIGS. 7 and 9, notch 42 of device 65 is designed to accommodate the origin of inferior oblique muscle 107. Similar to stopper 36 of device 50, stopper 37 is designed to prevent excessive advancement of device 65 toward optic nerve 96 through contact on the anterior border of inferior oblique muscle 107. Transversal part 18 has a distal end 58, a rounded edge 28, and a well or cavity 20 having an opening 64 (not shown) to scleral surface 14 (not shown) for holding an inner core similar to those described above in connection with FIGS. 10 and 11. Well 20 and opening 64 preferably have a generally oval shape.
Device 52 generally includes a body 39 having a convex, dome-shaped, orbital surface 12 and a concave, dome-shaped scleral surface 14 (not shown). Scleral surface 14 is designed with a radius of curvature that facilitates direct contact with sclera 100. Most preferably, scleral surface 14 is designed with a radius of curvature equal to the radius of curvature 91 of an average human eye 90. Orbital surface 12 is preferably designed with a radius of curvature that facilitates implantation under Tenon's capsule 101. When viewed from the top, body 39 preferably has a generally �L-shaped� geometry with a longitudinal part 15, a transversal part 18, and a knee 32 therebetween. Longitudinal part 15 and transversal part 18 are preferably joined at knee 32 to form an angle of about ninety degrees. Similar to notch 42 of device 50 of FIGS. 7 and 9, longitudinal part 15 and transversal part 18 of device 52 form a region 43 designed to accommodate the origin of inferior oblique muscle 107. Longitudinal part 15 has a proximal end 25 and a rounded edge 24. Transversal part 18 has a distal end 58, a rounded edge 28, and a well or cavity 20 having an opening 64 (not shown) to scleral surface 14 for holding an inner core similar to those described above in connection with FIGS. 10 and 11. Well 20 and opening 64 preferably have a generally oval shape.
The present invention is illustrated herein by example, and various modifications may be made by a person of ordinary skill in the art. For example, although the present invention is described hereinabove with reference to an ophthalmic drug delivery device having a generally �F-shaped�, �C-shaped�, or �L-shaped� geometry when viewed from the top, other geometries may be used, especially if they facilitate the placement of the device under the inferior oblique muscle and the location of pharmaceutically active agent over the macula when the device is implanted on the outer surface of the sclera and below the Tenon's capsule of the human eye.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS3416530Mar 2, 1966Dec 17, 1968Richard A. NessEyeball medication dispensing tabletUS3828777Nov 8, 1971Aug 13, 1974Alza CorpMicroporous ocular deviceUS4014335Mar 25, 1976Mar 29, 1977Alza CorporationOcular drug delivery deviceUS4300557Jan 7, 1980Nov 17, 1981The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesMethod for treating intraocular malignanciesUS4327725Nov 25, 1980May 4, 1982Alza CorporationOsmotic device with hydrogel driving memberUS4853224Dec 22, 1987Aug 1, 1989VisionexBiodegradable ocular implantsUS4946450Apr 18, 1989Aug 7, 1990Biosource Genetics CorporationGlucan/collagen therapeutic eye shieldsUS4997652May 31, 1989Mar 5, 1991VisionexBiodegradable ocular implantsUS5147647Dec 12, 1990Sep 15, 1992Sohrab DarougarOcular insert for the fornixUS5164188Nov 22, 1989Nov 17, 1992Visionex, Inc.Biodegradable ocular implantsUS5178635May 4, 1992Jan 12, 1993Allergan, Inc.Method for determining amount of medication in an implantable deviceUS5300114Aug 10, 1992Apr 5, 1994Allergan, Inc.Subconjunctival implants for ocular drug deliveryUS5322691Jun 29, 1993Jun 21, 1994Sohrab DarougarOcular insert with anchoring protrusionsUS5378475Feb 21, 1991Jan 3, 1995University Of Kentucky Research FoundationSustained release drug delivery devicesUS5403901Nov 24, 1993Apr 4, 1995Nestle S.A.Flexible, high refractive index polymersUS5443505Nov 15, 1993Aug 22, 1995Oculex Pharmaceuticals, Inc.Biocompatible ocular implantsUS5466466Apr 20, 1994Nov 14, 1995Lts Lohmann Therapie-Systeme Gmbh & Co. KgTherapeutic system for the retarded and controlled transdermal or transmucous administration of active substrates IIUS5476511Jul 21, 1993Dec 19, 1995Allergan, Inc.Subconjunctival implants for ocular drug deliveryUS5516522Mar 14, 1994May 14, 1996Agricultural And Mechanical CollegeBiodegradable porous device for long-term drug delivery with constant rate release and method of making the sameUS5632984Sep 28, 1994May 27, 1997Oculex Pharmaceuticals, Inc.Method of treatment of macular degenerationUS5679666 *Nov 21, 1994Oct 21, 1997Alcon Laboratories, Inc.Prevention and treatment of ocular neovascularization by treatment with angiostatic steroidsUS5710165 *Jul 6, 1994Jan 20, 1998SynthelaboUse of polyamine antagonists for the treatment of glaucomaUS5725493 *Dec 12, 1994Mar 10, 1998Avery; Robert LoganIntravitreal medicine deliveryUS5743274 *Mar 18, 1996Apr 28, 1998Peyman; Gholam A.Macular bandage for use in the treatment of subretinal neovascular membersUS5766242Mar 13, 1996Jun 16, 1998Oculex Pharmaceuticals, Inc.Biocompatible ocular implantsUS5766619May 4, 1993Jun 16, 1998Aiache; Jean-MarcPharmaceutical dosage form for ocular administration and preparation processUS5770592Jul 16, 1997Jun 23, 1998Alcon Laboratories, Inc.Prevention and treatment of ocular neovascularization using angiostatic steroidsUS5773019 *Sep 27, 1995Jun 30, 1998The University Of Kentucky Research FoundationImplantable controlled release device to deliver drugs directly to an internal portion of the bodyUS5797898Jul 2, 1996Aug 25, 1998Massachusetts Institute Of TechnologyMicrochip drug delivery devicesUS5824072 *Aug 14, 1996Oct 20, 1998Oculex Pharmaceuticals, Inc.Biocompatible ocular implantsUS5824073Sep 20, 1996Oct 20, 1998Peyman; Gholam A.Macular indentor for use in the treatment of subretinal neovascular membranesUS5830173Aug 1, 1997Nov 3, 1998Avery; Robert LoganIntravitreal medicine deliveryUS5836935Jan 28, 1997Nov 17, 1998Ashton; PaulImplantable refillable controlled release device to deliver drugs directly to an internal portion of the bodyUS5902598Aug 28, 1997May 11, 1999Control Delivery Systems, Inc.Sustained release drug delivery devicesUS5904144Mar 22, 1996May 18, 1999Cytotherapeutics, Inc.Method for treating ophthalmic diseasesUS5916584Oct 25, 1995Jun 29, 1999Daratech Proprietary LimitedControlled release container with core and outer shellUS6001386Apr 14, 1998Dec 14, 1999University Of Kentucky Research FoundationImplantable controlled release device to deliver drugs directly to an internal portion of the bodyUS6074661Sep 10, 1998Jun 13, 2000Allergan Sales, Inc.Sterile bioerodible occular implant device with a retinoid for improved biocompatabilityUS6110485Jul 16, 1999Aug 29, 2000Allergan Sales, Inc.Sterile bioerodible implant device with a retinoid for improved biocompatabilityUS6126687Oct 28, 1997Oct 3, 2000Peyman; Gholam A.Macular bandage for use in the treatment of subretinal neovascular membranesUS6146366Nov 3, 1998Nov 14, 2000Ras Holding CorpDevice for the treatment of macular degeneration and other eye disordersDE4022553A1Jul 16, 1990Jan 23, 1992Hund Helmut GmbhMedical contact lens - with recess contg. therapeutically or diagnostically active substanceEP0904787A1Mar 19, 1997Mar 31, 1999Santen Pharmaceutical Co., Ltd.Scleral plug containing proteinaceous medicineRU2149615C1 Title not availableWO1994005257A1Aug 27, 1993Mar 17, 1994Allergan IncSustained release of ophthalmic drugs from a soluble polymer drug delivery vehicleWO1995026734A1Mar 31, 1995Oct 12, 1995William R FreemanUse of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressureWO1995028984A1Apr 24, 1995Nov 2, 1995Escalon Ophthalmics IncTack for intraocular drug delivery and method for inserting and removing sameWO1996036377A1May 13, 1996Nov 21, 1996Optonol LtdIntraocular implant, delivery device, and method of implantationWO1997014415A1Oct 18, 1996Apr 24, 1997Faulding F H & Co LtdAnalgesic immediate and controlled release pharmaceutical compositionWO1998023228A1Nov 21, 1997Jun 4, 1998Alza CorpDirectional drug delivery stentWO1998043611A1Mar 17, 1998Oct 8, 1998Alza CorpDiffusional implantable delivery systemWO1999007418A2Aug 10, 1998Feb 18, 1999Allergan Sales IncSterile bioerodible implant device with improved biocompatability and methodWO1999011244A1Aug 28, 1998Mar 11, 1999Control Delivery Sys IncSustained release drug delivery devicesWO1999032104A1 *Dec 4, 1998Jul 1, 1999Alcon Lab IncUse of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glc1a glaucomaWO1999045920A2Mar 12, 1999Sep 16, 1999Juan Eugene DeThe use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammationWO2000037066A2Dec 22, 1999Jun 29, 2000Univ Johns Hopkins MedA method for the prophylactic treatment of cataracts* Cited by examinerNon-Patent CitationsReference1"A New Method for Posterior Sub-Tenon's Drug Administration", Nesterov et al., Ophthalmic Surgery, vol. 24, No.1, Jan. 1993, pp. 59-61.2"Bausch & Lomb and Control Delivery Systems Agree to Develop Breakthrough Therapeutic Products for Severe Eye Diseases"; Business Wire via First!; NewsEdge Corp.; Jun. 14, 1999; 4 pp.3"Method of Placing Irrigation System into Tenon's Space", E.I. Sidorenko, et al., Abstract of Russian Patent No. RU 2123314, issued Dec. 20, 1998, 1 pg.4DIALOG(R) File 266:FEDRIP database record; Identifying No. 122098; "Implantation of a Sub-Tenon Drug Delivery Device Loaded with a Test Article in Rabbits and Distribution of the Test Article in Ocular Tissues"; Compiled and distributed by NTIS: 1 page, Aug. 14, 1998.5DIALOG(R) File 266:FEDRIP database record; Identifying No. 131476; "Ocular Bioavailability of AL-3789 and AL-4940 After Sub-Tenon's Injection of AL-3789 Ophthalmic Suspensions in New Zealand White Rabbits"; Compiled and distributed by NTIS; 1 page, Sep. 1997.6DIALOG(R) File 266:FEDRIP database record; Identifying No: 122098; "Implantation of a Sub-Tenon Drug Delivery Device Loaded with a Test Article in Rabbits and Distribution of the Test Article in Ocular Tissues"; Compiled and distributed by NTIS; 1 page; Aug. 14, 1998.7DIALOG(R) File 266:FEDRIP database record; Identifying No: 134284; "Implantation of a Sub-Tenon Drug Delivery Device Loaded with a Test Article in Rabbits and Distribution of the Test Article in Ocular Tissues"; Compiled and distributed by NTIS; 1 page, Jul. 1, 2000.8DIALOG� File 266:FEDRIP database record; Identifying No. 122098; "Implantation of a Sub-Tenon Drug Delivery Device Loaded with a Test Article in Rabbits and Distribution of the Test Article in Ocular Tissues"; Compiled and distributed by NTIS: 1 page, Aug. 14, 1998.9DIALOG� File 266:FEDRIP database record; Identifying No. 131476; "Ocular Bioavailability of AL-3789 and AL-4940 After Sub-Tenon's Injection of AL-3789 Ophthalmic Suspensions in New Zealand White Rabbits"; Compiled and distributed by NTIS; 1 page, Sep. 1997.10DIALOG� File 266:FEDRIP database record; Identifying No: 122098; "Implantation of a Sub-Tenon Drug Delivery Device Loaded with a Test Article in Rabbits and Distribution of the Test Article in Ocular Tissues"; Compiled and distributed by NTIS; 1 page; Aug. 14, 1998.11DIALOG� File 266:FEDRIP database record; Identifying No: 134284; "Implantation of a Sub-Tenon Drug Delivery Device Loaded with a Test Article in Rabbits and Distribution of the Test Article in Ocular Tissues"; Compiled and distributed by NTIS; 1 page, Jul. 1, 2000.Referenced byCiting PatentFiling datePublication dateApplicantTitleUS6646003 *Mar 7, 2002Nov 11, 2003Alcon, Inc.Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolacUS6669950 *Jul 1, 2002Dec 30, 2003Alcon, Inc.Ophthalmic drug delivery deviceUS6986900Nov 5, 2003Jan 17, 2006Alcon, Inc.Ophthalmic drug delivery deviceUS7094226Nov 12, 2003Aug 22, 2006Alcon, Inc.Ophthalmic drug delivery deviceUS7195774Aug 28, 2002Mar 27, 2007Carvalho Ricardo Azevedo PonteImplantable and sealable system for unidirectional delivery of therapeutic agents to tissuesUS7276050 *Mar 2, 2004Oct 2, 2007Alan FranklinTrans-scleral drug delivery method and apparatusUS7527621 *Aug 16, 2006May 5, 2009Second Sight Medical Products, Inc.Implantable drug delivery deviceUS7585517Sep 20, 2004Sep 8, 2009Macusight, Inc.Transscleral deliveryUS7749528Mar 15, 2004Jul 6, 2010Ricardo Azevedo Pontes De CarvalhoImplantable and sealable medical device for unidirectional delivery of therapeutic agents to tissuesUS7887508Mar 14, 2007Feb 15, 2011The University Of Southern CaliforniaMEMS device and method for delivery of therapeutic agentsUS7943162Dec 7, 2006May 17, 2011Alcon, Inc.Drug delivery deviceUS8167855Aug 25, 2004May 1, 2012Vista Scientific LlcOcular drug delivery deviceUS8222271Mar 23, 2007Jul 17, 2012Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditionsUS8231608May 8, 2009Jul 31, 2012Minipumps, LlcDrug-delivery pumps and methods of manufactureUS8231609May 8, 2009Jul 31, 2012Minipumps, LlcDrug-delivery pumps and methods of manufactureUS8287504Jul 22, 2010Oct 16, 2012Vista Scientific LlcOcular drug delivery deviceUS8308686May 28, 2010Nov 13, 2012The University Of Southern CaliforniaMEMS device and method for delivery of therapeutic agentsUS8348897May 8, 2009Jan 8, 2013Minipumps, LlcImplantable drug-delivery devices, and apparatus and methods for filling the devicesUS8377000Oct 1, 2010Feb 19, 2013Abbott LaboratoriesEnteral feeding apparatus having a feeding setUS8377001Oct 1, 2010Feb 19, 2013Abbott LaboratoriesFeeding set for a peristaltic pump systemUS8486278May 8, 2009Jul 16, 2013Minipumps, LlcDrug-delivery pumps and methods of manufactureUS8486960Jun 21, 2012Jul 16, 2013Santen Pharmaceutical Co., Ltd.Formulations and methods for vascular permeability-related diseases or conditionsUS8492400Feb 9, 2007Jul 23, 2013Santen Pharmaceutical Co., Ltd.Stable formulations, and methods of their preparation and useUS8529538Jul 3, 2012Sep 10, 2013Minipumps, LlcDrug-delivery pumps and methods of manufactureDE102007024642A1May 24, 2007Nov 27, 2008Eyesense AgHydrogel-Implantat f�r Sensorik von Metaboliten am AugeEP2329821A1Nov 29, 2006Jun 8, 2011GlaxoSmithKline LLCTreatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edemaWO2011039648A1Sep 29, 2010Apr 7, 2011Glaxo Wellcome Manufacturing Pte Ltd.Methods of administration and treatmentWO2011133964A2Apr 23, 2011Oct 27, 2011Massachusetts Eye And Ear InfirmaryMethods and compositions for preserving photoreceptor and retinal pigment epithelial cellsWO2012061045A2Oct 21, 2011May 10, 2012Massachusetts Eye And Ear InfirmaryMethods and compositions for preserving retinal ganglion cellsWO2013003467A2Jun 27, 2012Jan 3, 2013Massachusetts Eye And Ear InfirmaryMethods for treating ocular inflammatory disordersWO2013025840A1Aug 15, 2012Feb 21, 2013Massachusetts Eye And Ear InfirmaryMethods for preserving photoreceptor cell viability following retinal detachment* Cited by examinerClassifications U.S. Classification424/428, 424/422, 424/423, 424/427International ClassificationA61K9/00, A61M37/00, A61F9/00, A61F9/007Cooperative ClassificationA61K9/0051, A61F9/00781, A61F9/0017European ClassificationA61F9/00B2, A61K9/00M16BLegal EventsDateCodeEventDescriptionDec 11, 2013FPAYFee paymentYear of fee payment: 12May 31, 2011ASAssignmentFree format text: MERGER;ASSIGNOR:ALCON, INC.;REEL/FRAME:026376/0076Owner name: NOVARTIS AG, SWITZERLANDEffective date: 20110408Jan 11, 2010FPAYFee paymentYear of fee payment: 8Jan 9, 2006FPAYFee paymentYear of fee payment: 4Jun 24, 2003ASAssignmentOwner name: ALCON, INC., SWITZERLANDFree format text: CHANGE OF NAME;ASSIGNOR:ALCON UNIVERSAL LTD.;REEL/FRAME:014227/0335Effective date: 20020211Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALCON UNIVERSAL LTD.;REEL/FRAME:014201/0289Owner name: ALCON, INC. BOSCH 69HUNENBERG, (1)CH-6331Nov 29, 2000ASAssignmentOwner name: ALCON UNIVERSAL LTD., SWITZERLANDFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:YAACOBI, YOSEPH;REEL/FRAME:011335/0940Effective date: 20000915Owner name: ALCON UNIVERSAL LTD. BOSCH 69 HUNENBERG SWITZERLANRotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google